NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.
NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.
NKGen Biotech股票交易價格上漲，因公司宣佈了Troculeucel的相1階段中間數據以及相1/2a臨床試驗中第1名相2患者的投藥情況。
NKGen Biotech Shares Are Trading Higher After the Company Announced Early Interim Data From the Phase 1 Cohort and the Dosing of the First Phase 2 Patient in the Phase 1/2a Clinical Trial of Troculeucel.
NKGen Biotech公佈了Troculeucel1/2a期臨床試驗中第一期隊列的早期中期數據以及第一位2期患者的劑量，此後，該公司股價走高。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。